Loading news...
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) have received a consensus rating of "Hold" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada.
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT.
Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO®.
Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,570 shares of the company's stock, valued at approximately $931,000. Capital Fund Management S.A. owned approximately 0.09% of Amphastar Pharmaceuticals
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Serge Belanger - Needham & Company, LLC, Research Division Pavan Patel - BofA Securities, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for the future periods are forward-looking statements.
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.96 per share a year ago.
Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / November 6, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Amphastar Pharmaceuticals is rated a buy due to strong Q2 earnings, value metrics, and promising pipeline developments. AMPH beat revenue and EPS estimates in Q2, with BAQSIMI sales up 21% YoY, offsetting declines in legacy generics. The company is vastly expanding US manufacturing and advancing new drugs, including AMP-002 (recently FDA approved) and AMP-004 (insulin aspart generic).